List of Diagnostics Companies in Colorado - 15

AOA Dx is developing the next frontier in early-stage cancer detection for women through its pioneering work in glycolipids and proprietary biomarker technology. Our revolutionary tumor marker ganglioside platform, GlycoLocate™, is paving the way for life-saving early cancer detection. In a first of its kind, AOA Dx is developing AKRIVIS GD™, an early-stage liquid biopsy test for ovarian cancer, that has proven excellent sensitivity and specificity in a recent study. We foresee novel tumor biomarker gangliosides as the future for diagnosis, prognosis, monitoring, and eventually targeted therapies across multiple cancers. AOA Dx was co-founded by three experts and passionate advocates of women's health, who have worked together at two previous diagnostic startups, that both resulted in successful exits upon commercialization. AOA Dx, a Y combinator and VC backed company, raised an oversubscribed Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combinator 2. MassChallenge 3. Springboard Enterprises 4. MassMedic Ignite 5. Inc Magazine Top 100 Female Founders 6. Women's Health Innovation Summit Award 7. Massachusetts Life Sciences Center MassNextGen Award 8. The Wave Summit's Emerging Women Founder in Bio Award 9. The Eddies Award 10. Bloomberg New Economy Catalyst www.aoadx.com

ArcherDX is developing and seeking regulatory clearances for next-generation sequencing (NGS) diagnostics to help solve for the underutilization of targeted cancer therapies.

Arthroventions™ is improving the quality of life for patients with joint disease by developing technologies that enable more effective joint care. Over 70 million Americans (1 in 5) have a form of joint disease. It impacts more people than cancer, there is no cure, and the longer and more active a lifestyle, we live the more likely we will experience it. At Arthroventions, we believe the synovial fluid is the key to diagnosing and treating the different types of joint disease, including Osteoarthritis and Rheumatoid Arthritis. Unlike other chronic diseases, such as cancer, there are no diagnostics assays that can differentiate between disease phenotypes or to predict drug responsiveness. This results in patients receiving ineffective treatments based on physician and payer preference. Our first product line is a Class I medical device that facilitates the aspiration/removal of synovial fluid from and the injection of therapeutics into the joint space, which it is estimated that 30% of these procedures miss the joint space. Our new approach reduces patient pain and decreases the probability of missing the joint space, thereby improving the delivery of therapeutics and patient comfort. Using our devices, physicians and providers can realize additional revenue with improved quality of care. Our products support all types of intra-articular injections, including corticosteroids, viscosupplementation, and new regenerative therapy products such as Platelet Rich Plasma (PRP), Bone Marrow Aspirate Concentrate (BMAC), and Adipose derived cells. Join us and take the first step towards more effective joint care.

We provide services in genomics, statistics, and information technology. Our services include Bayesian analysis, bioinformatics, biomarker development, biostatistics, data management, data pipelines, data science, epigenomics, genetics, genome-wide association, imputation, microarray analysis, multiomics, next-generation sequencing analysis, pharmacogenomics, polygenic risk scores, predictive modeling, project management, proteomics, reproducibility, software development, statistical computing, statistical genetics, and statistical programming. We also developed the Smokescreen® Genotyping Array, advancing research into addiction and treatment approaches. Our highly-skilled transdisciplinary team of experts, carefully assembled from leading research universities and industry, has been solving our clients' research challenges for almost two decades. Extensive experience with a wide range of cutting-edge methods and technologies means we can help ensure your project's success, and provide high-quality deliverables on time and within budget. Whether you have a critical issue, need help with every aspect of a new project—including coordinating complex projects—or only one part of an ongoing project, we can work with you to develop the optimal solution to meet your goals and objectives. Our team can be an integral part of the collaboration, and provide full-service support for all the stages of your research journey. We follow all U.S. Department of Health & Human Services standards for the security of electronic protected health information (HIPAA-compliant). We believe in reproducible, reusable, transparent, and extensible research, and do everything we can to put those values into practice. We are prepared to use our internal computing environment, cloud-computing environments, or client-provided environments, if preferred.

At CereHealth, our mission is to revolutionize healthcare through the power of artificial intelligence. We are committed to improving patient outcomes and enhancing the efficiency of clinical practices by providing cutting-edge AI-driven Clinical Decision Support Solutions (CDSS). Our purpose is to bridge the gap between data and insights, enabling healthcare professionals to make informed and precise decisions at every critical juncture. By harnessing the potential of AI, we aim to empower medical experts with real-time, evidence-based recommendations that promote accurate diagnoses, personalized treatment plans, and optimize patient care. Driven by our dedication to innovation and integrity, we envision a future where healthcare providers can seamlessly integrate AI into their workflows. Through continuous research, collaboration, and advancements in AI technology, we strive to be at the forefront of CDSS, setting new standards for excellence in healthcare decision-making. We are unwavering in our commitment to privacy and security, ensuring that patient data is treated with the utmost confidentiality and adhering to the highest standards of compliance. Our solutions are designed not only to support medical professionals but also to engender trust among patients, knowing that their well-being remains at the heart of every AI-driven recommendation. By working hand in hand with the medical community, we aim to foster a healthcare landscape where AI augments human expertise, leading to faster, more accurate diagnoses, reduced medical errors, and ultimately, improved patient outcomes. At CereHealth, we are dedicated to shaping a healthier tomorrow through the synergy of AI and medical wisdom.

Corgenix is part of the SEBIA Group. Located outside of Denver, Colorado, USA, Corgenix is a CAP/CLIA accredited laboratory specializing in clinical studies, clinical trial management and physician-ordered patient testing. Corgenix is also a experienced in CDMO—Contract Development and Manufacturing Organization. Corgenix is a highly capable strategic partner with history of success; our main client groups are Biotech companies, Pharmaceutical industry, Cancer Centers, and Academic laboratories. Strategic collaborations have covered all aspects of the IVD process –development, quality control, regulatory compliance, manufacturing (We are ISO-13485:2016, an FDA registered facility and GMP compliant), warehousing, distribution, product support, and commercialization. . Whether you need support for research, clinical trial testing or contract clinical testing services, we are here to serve. Above all, we believe in clear communication and transparency. We take a cross-functional team approach to our projects, fully engaging with our clients throughout the project. What do you need? Please contact us to see how we can support your business strategy!

Darwin Biosciences specializes insaliva-based diagnostic tests for infectious disease. We are developing diagnostics that can identify people who are asymptomatic or pre-symptomatic for common infectious diseases, including COVID-19. Some of our products are being designed for clinical use. Others are expected to be hand-held and self-administered, so that people can monitor their own health at home or when reporting for work at venues where vulnerable people (i.e. nursing homes, hospitals) or many people (delivery personnel, airport employees) are being served.

Flagship Biosciences is a leader in spatial biology and biomarker analysis, bringing innovative approaches to clinical research and drug development. The company delivers the most accurate and informative data available in the field of spatial biology and biomarker services.

Foresight Diagnostics is a precision medicine company developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD) for aid in patient management that is funded by leading diagnostics VC firms in Silicon Valley. Foresight’s cell-free DNA testing platform was developed in the labs of two prominent professors at Stanford University and is backed by several major peer-reviewed publications. The company has garnered significant partnering interest from multiple pharmaceutical companies in oncology and is poised for rapid growth. Foresight Diagnostics is headquartered in Aurora, Colorado.

GT Molecular develops ultrasensitive Molecular Assays, Digital PCR and qPCR Tests End-to-End solutions for cancer detection and waterborne pathogens including SARS-CoV-2. Detect as little as 1-3 molecules of target DNA

KromaTiD, Inc. provides products and services for mutation detection and disease diagnosis. KromaTiD’s patented dGH™ chromosome imaging platform enables detection of all types of chromosomal rearrangements including previously undetectable cryptic inversions.

Metabiomics has developed a new type of microbiome diagnostic test for early detection and monitoring of polymicrobial and immunological diseases such as inflammatory bowel disease, colon cancer, HIV infection, alcoholic liver disease, and others that are non-invasive, lower cost, more sensitive and accurate than currently available diagnostic procedures. For the past 10 years, Metabiomics has been a pioneer in human microbiome research specializing in functional metagenomics and systems biology applied to advances in microbial DNA sequencing methods, clinical research, and in vitro diagnostics. Our on-going clinical research is unraveling some of the secret relationships between human microbial communities, immunology, and health. Our research collaborations with Diversigen, the Harvard Chan School of Medicine, Penn State University and George Mason University Microbiome Analysis Center and several medical research institutions are focusing on microbial biomarkers and immunological responses in intestinal dysbiosis, colon disease and cancer, liver disease, and other immunological diseases.

Orbit Genomics is transforming complex disease diagnosis, treatment and prevention through early warning genomics. Our patent pending OrbiSeq™ platform analyzes novel genomic markers which uniquely reflect not only inherited predisposition to disease, but also risk acquired from lifestyle and environmental exposures. OrbiSeq can be applied to diagnose, treat and help prevent complex diseases including cancer, heart disease and neurological diseases. Our first product is an aid to diagnosis for lung cancer, the world’s deadliest cancer and the only major one without a routine screening test. Diagnosis often requires an expensive and invasive biopsy. Our simple blood test will eliminate unnecessary biopsies.

The SomaScan® Platform is the only proteomics platform on the market that scales with precision.

TopoGEN is a research diagnostics company that provides innovative products and services for researchers working with topoisomerases and engaged in mechanism based drug discovery and development. The company was created by topo research active scientists who understand the needs and the restraints placed on other cancer researchers or those working in areas peripheral to topoisomerases. Top-selling products include: -Drug Screening Kits to identify topoisomerase active drugs for use in cancer chemotherapy and antibacterial applications -Assay Kits for assaying prokaryotic and eukaryotic topoisomerases (type I, II, IV, gyrase), both in vitro and in vivo -A complete line of DNA substrates and DNA cleavage targets, topoisomerase inhibitors, topoisomerase antibodies, and kit replenishment reagents Our contract screening service offers you powerful, mechanism based custom screens developed and conducted entirely in house. Our cell based (in vivo) screens for detecting topoisomerase I and II poisons in the context of the cancer cell represents the new gold standard for identification of novel anti cancer agents. Since the early 1990s TopoGEN has maintained a dedicated clientele around the world. We offer substantial product support, data interpretation and consultation advice. When you become our customer, we become your partner in research. We review your data and offer valuable input. Please contact us for further information about how we can assist your research goals.